ASX Announcement Imugene Receives $2.1m R&D Tax Refund Sydney, Australia, 16 November 2026: Imugene Limited (ASX: IMU), a clinical-stage immuno- oncology company, is pleased to announce it has received its research and development (R&D) tax refund for the 2026 financial year, totaling A$2,145,157....
Imugene Receives $2.1M R&D Tax Refund
Filed with ASX · · 1 page · English
Summary by 6ix AI
Imugene Ltd has announced the receipt of a research and development tax refund for the financial year, which will support ongoing clinical activities. This funding will assist in patient recruitment for a specific phase of their clinical study involving a CAR T therapy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Story so far
Earlier from Imugene
- Director Resignation and Committee Changes
- Results of 2026 Annual General Meeting
- AGM Presentation
- Imugene selected for Poster Presentation at 2026 ASH Meeting
- Positive amendments to Convertible Notes
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene